POH04 Treatment of medically intractable SUNCT and SUNA with occipital nerve stimulation

ObjectivesTo report on the outcome and follow-up of 7 medically intractable SUNCT and SUNA patients treated with ONS.BackgroundSUNCT and SUNA are primary headaches characterised by repeated attacks of very severe headaches in association with cranial autonomic features that usually occur several tim...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neurology, neurosurgery and psychiatry Vol. 81; no. 11; pp. e51 - e52
Main Authors: Matharu, M, Watkins, L, Shanahan, P
Format: Journal Article
Language:English
Published: London BMJ Publishing Group Ltd 01-11-2010
BMJ Publishing Group LTD
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ObjectivesTo report on the outcome and follow-up of 7 medically intractable SUNCT and SUNA patients treated with ONS.BackgroundSUNCT and SUNA are primary headaches characterised by repeated attacks of very severe headaches in association with cranial autonomic features that usually occur several times daily. They can be medically intractable, in which case neurally destructive or cranially invasive treatments can be offered. ONS offers a nondestructive and relatively low-risk surgical alternative.MethodsSeven medically intractable patients (6 SUNCT, 1 SUNA) had bilateral ONS implants. Data were collected retrospectively for demographics, diagnosis, previous treatments, ONS settings, preimplantation and postimplantation headache characteristics, patients' estimates of change in headaches and complications.ResultsAt a median follow-up of 24 months (range 4–29), four patients reported a substantial improvement (95–100%), one reported moderate benefit (50%), one patient reported a temporary marked benefit (50%) for 6 months followed by recurrence of headache at the pre-ONS baseline, and one failed to respond. The onset of the benefit was rapid (within 2 weeks) with attacks recurring rapidly when the stimulator was switched off or malfunctioned. One patient developed hemicrania continua 1 month after implantation and was successfully treated with indometacin.ConclusionONS appears to offer a safe treatment option, without significant morbidity, for medically intractable SUNCT and SUNA.
Bibliography:ark:/67375/NVC-7G95P258-L
ArticleID:jnnp226340.138
istex:1E3801A26C35881DA971291CC783F279F44471A2
local:jnnp;81/11/e51-d
href:jnnp-81-e51-4.pdf
ISSN:0022-3050
1468-330X
DOI:10.1136/jnnp.2010.226340.138